ArticleAmerican journal of translational research2026
Effects of sacubitril/valsartan combined with ivabradine in treating cardiorenal syndrome.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of sacubitril/valsartan combined with ivabradine in treating cardiorenal syndrome (CRS).
methodsInformation from 120 selected participants was retrospectively analyzed and divided into an experimental group (n=60) and a control group (n=60). The control group received sacubitril/valsartan alone, while the experimental group received sacubitril/valsartan plus ivabradine. Clinical efficacy, blood lipids, cardiac and renal function, and oxidative stress were observed in both groups.
resultsThe experimental group showed better clinical efficacy, lipid metabolism, cardiac function, renal function, and oxidative stress than the control group, and a lower incidence of major adverse cardiovascular events (MACE) (all P<0.05).
conclusionSacubitril/valsartan combined with ivabradine is effective in treating CRS patients, with superior efficacy across various indicators and its usage has a lower incidence of MACE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.